BTSG Earnings Prediction
The chart below shows how BTSG performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BTSG sees a +6.49% change in stock price 10 days leading up to the earnings, and a +3.66% change 10 days following the report. On the earnings day itself, the stock moves by -0.74%. This data can give you a slight idea of what to expect for the next quarter's release.
BTSG Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
BTSG Earnings Analysis
Brightspring Health Services Inc Corporation (BTSG.O) Earnings Conference Call
Positive
Earnings Per Share Beat: BrightSpring Health Services, Inc. reported an EPS of $0.22, exceeding expectations of $0.19.
Strong Revenue Growth: Total revenue growth of 29% year-over-year in Q4 2024, with full year revenue reaching $11.3 billion, representing 28% growth year-over-year.
Pharmacy Solutions Revenue Growth: Pharmacy Solutions revenue grew by 34% year-over-year, totaling $8.8 billion for the full year 2024.
Provider Services Revenue Growth: Provider Services segment revenue grew by 9% year-over-year, totaling $2.5 billion for the full year 2024.
Adjusted EBITDA Growth: Adjusted EBITDA for full year 2024 was $588 million, reflecting a 16% growth year-over-year.
Customer Satisfaction Excellence: The company achieved high customer satisfaction scores, with Net Promoter Scores of 98 and 100 for Onco360 and CareMed, respectively.
High-Quality Home Health Services: 85% of home health branches achieved a CMS star rating of 4 or 5 out of 5, indicating high-quality service.
Procurement and Automation Initiatives: The company has implemented over 100 procurement and automation programs to drive efficiency and cost savings.
Infusion Revenue Surge: Infusion and Specialty revenue grew by 42% year-over-year in Q4, driven by strong script growth.
Pharmacy Revenue Growth: Home and Community Pharmacy revenue grew by 17% year-over-year in Q4, indicating strong market demand.
EBITDA Margin Expansion: Provider Services segment adjusted EBITDA margin expanded by 70 basis points year-over-year to 15.2% in Q4.
Revenue and EBITDA Guidance Increase: The company is increasing its revenue and adjusted EBITDA guidance for 2025, reflecting confidence in continued growth.
Negative
Gross Profit vs. Revenue Growth: Total company gross profit growth of only 14% in Q4 compared to 29% revenue growth, indicating potential margin pressure.
Pharmacy Solutions Margin Analysis: Adjusted EBITDA margin for Pharmacy Solutions was only 4.7%, which may suggest inefficiencies in that segment despite revenue growth.
High Debt Leverage Ratio: Net debt outstanding is approximately $2.7 billion with a leverage ratio of 4.16x, indicating a high level of debt relative to earnings.
Interest Expense Impact: The company is facing significant interest expenses, projected at approximately $43 million per quarter, which could impact profitability.
Divestiture Impacts on Operations: The divestiture of the community living business, while expected to streamline operations, may also indicate challenges in that segment's performance.
Provider Services Growth Analysis: Despite overall revenue growth, the Provider Services segment only achieved 11% growth, which is lower than the growth rates of other segments, suggesting potential weaknesses in that area.
BTSG FAQs
How does BTSG typically perform around its earnings report dates?
Is Brightspring Health Services Inc (BTSG) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BTSG Earning Call Sentiment
BrightSpring Health Services, Inc. Common Stock (NASDAQ:BTSG) Q4 2024 Earnings Call Transcript
BTSG.O
-0.56%Positive
The company demonstrated strong financial performance with significant revenue and EBITDA growth, along with optimistic guidance for the future. Despite some competitive and regulatory risks, the Q&A section highlighted continued expansion plans and operational efficiencies. The lack of a share repurchase program is a minor negative, but overall, the positive earnings surprise and raised guidance outweigh concerns, suggesting a likely positive stock price movement.
